GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript

Emma Walmsley: Right. And then last question, please.

Operator: Our final question comes from Simon Baker from Redburn.

Simon Baker: I promise I’ll be quick. A question on BLENREP. Tony, back in November on the Q3 call, you mentioned that there was ongoing analysis involving soluble BCMA as a prognostic indicator. I just wonder if you could give us any update on the findings from that. And related to BLENREP, I see DREAMM-7 and DREAMM-8 have moved from H1 into H2. Is that shifting here for event-driven studies or is there anything else we should be aware of?

Emma Walmsley: You cut out just to the second part of that question, but I think it was 1 of the implications in the first half, second half on 7 and 8. But — sorry, for you, Tony.

Tony Wood: Yes. Look. So Simon, the analysis that we discussed in terms of soluble BCMA and other markers that might explain the crossover that we see in DREAMM-3 is still ongoing. As far as DREAMM-7 and DREAMM-8 outcomes are concerned, we’re now targeting a more complete picture of those. And if I remind you, these are 2 studies that are looking at BLENREP in combination versus standard of care in contrast to DREAMM-3, which was BLENREP and monotherapy. We’re expecting to be able to provide a deeper update on those at the end of the year. And not much more to say at this stage, Simon. The analysis is ongoing. We’ll bring this, when I’ve got a clearer picture.

Emma Walmsley: Thanks. Great. Well, thank you, everyone. I hope this has been an efficient call for you. We’re delighted with the momentum and progress in the business. We look into 2023 with confidence and do so also for our medium-term outlook and beyond. We look forward to staying connected and keeping you updated in coming quarters and along the way. Thanks very much. Bye.